News headlines about Celldex Therapeutics (NASDAQ:CLDX) have been trending somewhat positive this week, Accern reports. The research group identifies positive and negative media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Celldex Therapeutics earned a news sentiment score of 0.12 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 46.9328507059593 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Several analysts have weighed in on CLDX shares. WBB Securities reiterated a “buy” rating and issued a $10.00 price objective on shares of Celldex Therapeutics in a research report on Wednesday, December 6th. HC Wainwright reiterated a “buy” rating on shares of Celldex Therapeutics in a research report on Tuesday, November 7th. Finally, BidaskClub upgraded Celldex Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, January 5th. Three equities research analysts have rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company’s stock. Celldex Therapeutics presently has an average rating of “Hold” and a consensus price target of $7.05.

Shares of Celldex Therapeutics (CLDX) opened at $2.84 on Friday. Celldex Therapeutics has a 12-month low of $2.20 and a 12-month high of $3.94. The firm has a market capitalization of $391.72, a P/E ratio of -2.81 and a beta of 2.73.

Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.27) by $0.07. Celldex Therapeutics had a negative return on equity of 46.94% and a negative net margin of 1,088.58%. The firm had revenue of $3.90 million during the quarter, compared to the consensus estimate of $1.30 million. During the same quarter in the previous year, the company posted ($0.29) earnings per share. The business’s revenue was up 77.3% on a year-over-year basis. equities analysts expect that Celldex Therapeutics will post -0.93 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Celldex Therapeutics (CLDX) Receives Coverage Optimism Score of 0.12” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another publication, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The legal version of this article can be viewed at https://www.thecerbatgem.com/2018/01/28/celldex-therapeutics-cldx-receives-coverage-optimism-score-of-0-12.html.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.

Insider Buying and Selling by Quarter for Celldex Therapeutics (NASDAQ:CLDX)

Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.